Skip to content

In-Use Test With a Cosmetic Product

In-Use Test With a Cosmetic Product (WO 4260) for Topical Use on the Scalp

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03252730
Enrollment
34
Registered
2017-08-17
Start date
2017-01-30
Completion date
2017-02-27
Last updated
2017-08-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dermatitis, Atopic

Keywords

Dry scalp, Itchy scalp

Brief summary

The aim of the study is to evaluate the tolerance of the product WO 4260 by a dermatologist. Additional objectives of this clinical in-use study are to evaluate the cosmetic features and acceptance of the product by means of a questionnaire in an interview situation and by skin hydration measurements on the scalp.

Interventions

OTHERWO 4260 Cosmetic Product for Topical Use

Application on the hair scalp at least once a day over four weeks

Sponsors

SIT Skin Investigation and Technology Hamburg GmbH
CollaboratorOTHER
Dr. August Wolff GmbH & Co. KG Arzneimittel
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* age: ≥ 18 years * sex: approx. 50% male and approx. 50% female * users of hair tonic for dry scalp * dry, itchy scalp prone to atopic eczema / atopic dermatitis

Exclusion criteria

* any deviation from the above-mentioned criteria * users of sour hair rinse * subjects who wash their hair more than once a day * other dermatological disorders (scars, moles) on the scalp * known incompatibilities to cosmetics and ingredients of cosmetic test products (please see INCI) * topical medication in the test area within 1 month prior to study start * systemic medication with anti-inflammatory agents and antibiotics within 2 weeks prior to starting of the study * systemic medication with retinoids, antihistamines and/or immunomodulators (e.g. cortisone, corticosterone, chemotherapeutic agents) within 4 weeks prior to starting of the study * systemic illness of the subject at the beginning of the study * pregnancy and period of breastfeeding

Design outcomes

Primary

MeasureTime frameDescription
Tolerance of the Test Product on the Scalpafter 4 weeks of treatmentChange from Baseline Tolerance on the Scalp at 4 weeks

Secondary

MeasureTime frameDescription
Skin Hydration of the Scalpbefore product treatment; after 2 and 4 weeks of treatmentThe measurement is performed using the DermaLab® device with the moisture pin (Cortex Technology)
Performance of the Test Productafter 4 weeks of treatmentSubjective assessment of product performance in a questionnaire-based interview
Tolerance of the Test Product on the Scalpafter 2 weeks of treatmentDermatological assessment of the Scalp concerning the Tolerance of the Test Product regarding erythema, edema dryness etc. Each item is scored 0=absent to 4=extreme.

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026